Everest Medicines Ltd
HKEX:1952
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.54
39.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Everest Medicines Ltd
Total Current Liabilities
Everest Medicines Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Everest Medicines Ltd
HKEX:1952
|
Total Current Liabilities
¥300.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Liabilities
¥12.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Liabilities
¥1.4B
|
CAGR 3-Years
100%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Current Liabilities
¥2.7B
|
CAGR 3-Years
48%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Current Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
41%
|
CAGR 10-Years
32%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Current Liabilities
¥22.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
32%
|
CAGR 10-Years
71%
|
|
Everest Medicines Ltd
Glance View
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
See Also
What is Everest Medicines Ltd's Total Current Liabilities?
Total Current Liabilities
300.1m
CNY
Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Total Current Liabilities amounts to 300.1m CNY.
What is Everest Medicines Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
13%
Over the last year, the Total Current Liabilities growth was -66%. The average annual Total Current Liabilities growth rates for Everest Medicines Ltd have been 17% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
